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Abstract
ERRa is an orphan member of the nuclear receptor family, the complete inactivation of which confers resistance to bone
loss induced by ageing and estrogen withdrawal to female mice in correlation with increased bone formation in vivo.
Furthermore ERRa negatively regulates the commitment of mesenchymal cells to the osteoblast lineage ex vivo as well as
later steps of osteoblast maturation. We searched to determine whether the activities of ERRa on osteoblast maturation are
responsible for one or both types of in vivo induced bone loss. To this end we have generated conditional knock out mice in
which the receptor is normally present during early osteoblast differentiation but inactivated upon osteoblast maturation.
Bone ageing in these animals was similar to that observed for control animals. In contrast conditional ERRaKO mice were
completely resistant to bone loss induced by ovariectomy. We conclude that the late (maturation), but not early
(commitment), negative effects of ERRa on the osteoblast lineage contribute to the reduced bone mineral density observed
upon estrogen deficiency.
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Introduction
Bone remodeling is a dynamic process in which resorption
exerted by osteoclasts is compensated for by formation exerted by
osteoblasts. Although normally tightly regulated, this equilibrium
can be disrupted under various circumstances [1,2]. For instance,
during ageing mesenchymal cells (MCs, the osteoblast progenitors)
become more prone to differentiate into adipocytes than into
osteoblast, in fine leading to a relative excess osteoclast activity. In
contrast estrogen deficiency in post-menopause women results in
derepressed osteoclast differentiation and activity that is not
compensated for by a similarly increased osteoblast activity.
Ageing and menopause thus both lead to increased bone fragility
(i.e. osteoporosis) and enhanced fracture risk. Given the global
ageing of the world population, osteoporosis and its consequences
now represent a major public health problem, in particular in
females. Treatments against post-menopause osteoporosis have up
to now generally aimed at reducing osteoclast activities, in
particular via hormone replacement therapies [3–5]. Due to
controversial side effects of the latter treatments, the possibility of
enhancing osteoblast differentiation and/or activities (bone
anabolism) could appear as a promising approach [6,7].
MCs differentiation into osteoblast has increasingly been
characterized including at the level of the sequential expression
of functional markers. Two transcription factors, Runx2 and Osx,
are instrumental in the first steps of this cascade and precede and/
or regulate the expression of later markers, which reflect osteoblast
maturation. These include collagen 1a (Col1a), alkaline phospha-
tase (ALP), osteocalcin and osteopontin [8].
ERRa belongs to the nuclear receptor family, the members of
which act as transcription factors [9]. Although no natural ligand
has been identified to date for ERRa (which is thus referred to as
‘‘orphan receptor’’), synthetic compounds have been isolated that
modulate its activities and/or protein stability [10–13]. High
expression of ERRa in various human cancer types is correlated to
poor prognosis (reviewed in [14]). Furthermore the receptor has
been shown to promote tumorigenicity and angiogenesis in human
carcinoma cells xenografted onto Nude mice ([15–17], reviewed in
[18]), suggesting that inhibition of ERRa could be beneficial in
cancer treatment [19]. Several reports have demonstrated that
ERRa is a key positive regulator of various metabolic functions,
controlling lipid uptake, fatty acid oxidation, the tricarboxylic acid
cycle, oxidative phosphorylation and mitochondrial biogenesis
(reviewed in [20,21]). In addition, ERRa impacts on MCs
differentiation, promoting commitment towards the adipocyte
pathway [22] while inhibiting the osteoblast one [23,24]. Indeed,
when set in differentiation ex vivo, MCs originating from ERRa
knock-out (ERRaKO) mice display a higher and earlier expression
of Runx2, Col1a, ALP and osteocalcin, associated with increased
mineralization capacities. Mechanistically ERRa has been sug-
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gested to modulate Wnt signaling [25] whereas the closely related
ERRc receptor (which also represses osteoblast differentiation)
impairs Runx2 transcriptional activities [26]. In addition to these
early effects on MCs commitment, ERRa may impact on later
steps of osteoblast differentiation. Indeed, the enhanced ex vivo
differentiation of ERRaKO-originating MCs can be reverted by
re-expression of the receptor after the onset of differentiation,
suggesting that ERRa-deficient MCs still display a certain level of
plasticity [24]. Furthermore, the expression of osteopontin, an
inhibitor of mineralization and late marker of osteoblast differen-
tiation, is down regulated in ERRa-deficient osteoblasts, in
contrast to other earlier markers. In vivo studies have shown that
the bone mineral density of female ERRaKO mice is not reduced
upon ageing, in contrast to the situation in wild type animals
[23,24]. Furthermore, these mice also resist to the bone loss
resulting from estrogen withdrawal (obtained by ovariectomy).
These phenomena are associated with an increased bone
formation rate without any modification in bone resorption,
indicating that osteoblasts, not osteoclasts, are the major cellular
effectors mediating these resistances. In contrast, male ERRaKO
mice were indistinguishable from wild type animals both in terms
of bone ageing and sensitivity to androgen deficiency. Inactivating
ERRa may thus be beneficial in females to protect bone against
the deleterious impacts of ageing and estrogen deficiency by
promoting bone anabolism (reviewed in [27]).
It is unknown whether only one or both the early and late (as
defined above) effects of ERRa on osteoblast differentiation
contribute to which in vivo resistance. To investigate this question,
we have used the Cre-Lox technology to engineer mice in which
ERRa is specifically inactivated during the late phase of osteoblast
differentiation. We here report that female conditional ERRaKO
mice resist to bone loss induced by ovariectomy but not to the one
induced by natural ageing. ERRa thus contributes to estrogen
deficiency-induced bone loss through its inhibitory activities on
osteoblast maturation. Moreover, our results describe an animal
model in which age-related and hormone-deficiency-related bone
loss in females can be clearly uncoupled.
Results
To generate a conditional knock-out mouse model for ERRa,
we used ERRafl/fl mice in which ERRa exon 2 was flanked by
loxP sites. These animals were crossed with Col1a-Cre mice [28].
The latter animals express the Cre recombinase under the control
of a collagen 1a promoter fragment, which is selectively active in
early osteoblasts, only after the onset of differentiation. The
resulting mice (ERRaDOBDOB, Col1aCre/+) are thus predicted to
be inactivated for ERRa only in maturing osteoblasts and not in
mesenchymal stem cells or early committed osteoblast progenitors
(Fig. 1A). Genotyping using specific primer sets detected the floxed
allele in all tissues tested, whereas recombination only occurred in
bone (long bone and skull) but not in ‘‘soft’’ (i.e. bone-free) tissues
(Fig. 1B). This recombination appears only partial at the organ
level likely due to the unavoidable presence of osteoclasts and non-
bone contaminating cells (e.g. blood cells) as well as to the
heterogeneity in the stages of maturation in which osteoblasts are
in bone. ERRafl/fl and ERRaDOB/DOB,Col1aCre/+ mice are
hereafter referred to as control and conditional knock-out (cKO)
mice, respectively.
Due to the above-mentioned tissue heterogeneity, a decrease of
ERRa expression could not be measured in bone in vivo. We thus
turned to an ex vivo model in which pre-osteoblasts from mice
calvaria (cranial vault) were set in culture and allowed to
differentiate into osteoblasts. At the beginning of differentiation,
ERRa protein was equally (albeit weakly) detected in cells from
control and cKO mice (Fig. 2A). After five days of differentiation,
ERRa expression was enhanced in control cells as expected [29]
whereas it was dramatically lower in cKO-originating cells. ERRa
loss appeared only partial, which can be due to the heterogeneity
of the cell culture that also contains fibroblasts. We thus examined
the expression of ERRa by immunofluorescence in cells expressing
Col1a (i.e. differentiating osteoblasts) (Fig. 2B). In control cultures,
ERRa was expressed in the nucleus of these cells, as expected.
However, in cKO-originating cells, the receptor was undetectable
in Col1a-expressing cells, demonstrating a complete deletion of
ERRa in maturing osteoblasts.
We next analyzed the differentiation parameters of these cells.
We found that, in the absence of ERRa (cKO-originating cells),
alkaline phosphatase (ALP) activity was enhanced as compared to
control cells, as evidenced by a greater number of labeled foci and
Figure 1. Validation of ERRa conditional knock-out approach.
A. General strategy used. Exon 2 (E2; encoding the first zinc finger in
the DNA binding domain) of the ERRa gene was flanked by loxP sites in
ERRafl/fl mice (here after referred to as control [c] mice). Crossing these
mice with Col1a-Cre animals resulted in ERRaDOBDOB,Col1aCre/+ mice
(hereafter referred to as conditional knock-out [cKO] animals), which
display E2 deletion specifically in maturing osteoblasts. Location of PCR
primers (see sequences in Material and Methods section) for the
detection of the various alleles is depicted. Note that the gene structure
is not drawn to scale. B. Genotyping of ERRa alleles. PCR using the
indicated primers were performed using DNA extracted from the
indicated organs. Upper panel, detection of the floxed allele (506 bp) in
all organs tested; lower panel, detection of the recombinant allele
(386 bp) in skull vault and long bone. M: size marker; 2: blank PCR (no
DNA).
doi:10.1371/journal.pone.0054837.g001
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global enzymatic activity (Fig. 2C). Mineralizing activity was also
dramatically enhanced in cKO cultures as compared to control
ones (Fig. 2D). In the absence of ERRa, the expression (measured
by real time PCR) of middle to late differentiation markers such as
Col1a, ALP and osteocalcin (Ocn) was transiently enhanced (after
5 days of differentiation) and thereafter normalized, suggesting
a time-dependent effect of the receptor (Fig. 3A). In contrast,
expression of osteopontin, an ERRa direct target gene [30], was
reduced after 10 days of differentiation. Interestingly these
variations of expression are identical to those observed when
analyzing cells originating from complete (i.e. not conditional)
ERRaKO mice [24]. Reintroduction of ERRa by lentiviral
infection reversed the expression of the differentiation markers
(Fig. 3B). However, the expression of Runx2, an early differen-
tiation inducer (the expression of which precedes that of Col1a;
[8]) was not modified in cKO-originating cells as compared to
control ones nor upon reintroduction of ERRa. Since Runx2
activates the expression of Col1a, ALP and Ocn [8], this may
altogether suggest that ERRa counteracts Runx2 activity. In this
hypothesis, ERRa would act similarly to the closely related ERRc
[26]. To investigate this possibility, we performed cotransfection
experiments in C3H10T1/2 (mesenchymal) cells (Fig. 3C). Runx2
activated expression driven by its cognate response element (OSE;
[31]). However coexpression of ERRa or ERRc completely
blunted this effect. As a control, we verified that both ERRc and
ERRa were capable of activating transcription from their
common response element (ERRE), even if ERRa requires the
presence of the PGC-1a coactivator in these cells. Noteworthy,
Runx2 did not impact on ERR activities under these conditions.
Similar results were obtained in C2C12 cells, which are more
committed than C3H10T1/2 (data not shown).
Altogether this shows that i) ERRa is specifically inactivated in
cKO cells only after the onset of osteoblast differentiation ex vivo, ii)
the absence of the receptor under these conditions promotes late
osteoblast differentiation without impacting on early commitment
and differentiation steps. This validates the present cKO model as
a tool to study the in vivo effects of ERRa on osteoblast maturation
(as opposed to early MSC commitment).
The absence of ERRa in complete KO mice protects female
(but not male) animals against age-induced as well as against
ovariectomy-induced bone loss [24]. We thus first investigated
whether cKO mice were also protected from age-related bone loss.
To this end bone structural parameters were determined by X-ray
microtomography (microCt) comparing 14 wk and 24 wk old
females (Fig. 4). We observed an equal reduction of bone volume
(BV/TV, Fig. 4A), bone mineral density (BMD, Fig. 4B) and
trabecular number (Tb N, Fig. 4C) in both genotypes upon ageing.
Trabecular spacing (Tb Sp, Fig. 4D) was also equally enhanced,
reflecting the decreased number of trabeculae, in spite of constant
trabecular thickness (Tb Th, Fig. 4E), not expected to decrease
upon ageing. Noteworthy all these parameters displayed identical
values between control and cKO mice at a given age, indicating
Figure 2. Conditional inactivation of ERRa enhances late osteoblast functions. Pre-osteoblasts from control (c) or conditional knock-out
(cKO) mice were isolated from calvaria and allowed to differentiate ex vivo. A. Expression of ERRa detected in western blot after the indicated
differentiation period. Hsp90 was used as a loading control. B. Lack of ERRa expression in Col1a-expressing cKO cells. After 6 days of differentiation,
cells were fixed and stained with Dapi, anti-Col1a or anti-ERRa antibodies as indicated. C. Alkaline phosphatase activity was detected by whole cell
cultures staining after 10 days of differentiation (left panel), or by in vitro enzymatic assay relative to protein content (right panel) after the indicated
days of differentiation. The latter panel depicts a typical experiment (out of three) performed in triplicate. Data are expressed as average with error
bars representing S.D. D. Mineralization activity was detected by von Kossa staining after 15 days of differentiation. Whole culture wells are presented
on the left panels, field enlargements on the right ones.
doi:10.1371/journal.pone.0054837.g002
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that ERRa inactivation after the onset of osteoblast differentiation
does not protect against age-induced bone loss.
We next studied the bone structural parameters two weeks after
gonadectomy on control and cKO animals (Fig. 5). Female mice of
both genotype responded identically to ovariectomy (ovx) in terms
of reduced uterine thickness (Fig. 5A). In control female mice, we
observed the expected decrease in bone volume (Fig. 5B), bone
mineral density (Fig. 5C) and trabecular thickness (Fig. 5F) upon
ovx. As also expected the number of trabeculae was unchanged
(Fig. 5D) and a non-significant trend toward enhanced spacing
between trabeculae was observed (Fig. 5E). Strikingly, none of
these parameters were modified in ovariectomized cKO mice as
compared to sham-operated animals. The divergent response to
ovx of control and cKO mice can also be viewed on the
reconstructed 3D structures of trabecular bones (see Movies S1,
S2, S3, and S4). This situation is in full contrast with the one
prevailing in male mice in which orchidectomy (orx) led to
dramatically reduced bone volume (Fig. 5G) and mineral density
(Fig. 5H) both in control and cKO mice. We concluded that
inactivating ERRa during osteoblast maturation completely
protects against bone loss induced by hormonal deficiency,
selectively in females.
Discussion
Amongst other, ageing is associated with bone loss, leading to
osteoporosis (understood as bone fragility syndrome) and increased
fracture risk. Due to the global ageing of the human population
worldwide, osteoporosis is now a major health problem, being the
most common metabolic disorder of old age in humans [1,2].
During ageing bone formation by osteoblasts is impaired due
a decreased number and activity of osteoblasts, and concomitantly
bone resorption by osteoclasts is increased. Whereas both males
and females are subjected to age-associated osteoporosis, the
situation is further aggravated in females after menopause. The
cessation of ovarian function, resulting in highly decreased
circulating levels of estrogens, indeed leads to unimpaired
osteoclast differentiation and activity which is not compensated
for by an equivalent rise in osteoblast activity [32]. Although age-
related- and estrogen-deficiency-related bone loss essentially
originates in different cell compartments, it is expected that
enhancing bone anabolism (i.e. promoting bone formation by
osteoblasts) could be an efficient mean to counteract osteoporosis
in general [6,7].
In this line, we and others have shown that genetic inactivation
of the orphan nuclear receptor ERRa in mice leads to resistance to
bone loss induced by ovariectomy (used as a model for estrogen-
deficiency, thus mimicking menopause) or ageing [23,24]. In-
terestingly these phenotypes were not associated with a decrease in
osteoclast activity suggesting that ERRa does not modulate bone
resorption in vivo at least under the above-mentioned challenging
conditions. In contrast, ERRaKO animals displayed a higher
bone formation rate as compared to wild type ones, altogether
strongly suggesting that ERRa contributes to bone loss exclusively
through the effects it exerts in osteoblasts. It should however be
mentioned that ERRa has been shown to be required for
Figure 3. ERRa represses osteoblast differentiation markers. A. Evaluation of the expression of osteoblast differentiation markers by real time
PCR at the indicated time after differentiation of mouse calvarial cells. ALP: alkaline phosphatase; Ocn: osteocalcin; Opn: osteopontin. A single
representative experiment (out of three, performed in triplicate) is shown. Data are expressed relative to differentiation day 1 with error bars
representing S.D. B. Reintroduction of ERRa in cKO cells normalizes the expression of differentiation parameters. Lentivirus encoding human ERRa
was used to infect mouse calvarial cells induced in osteoblastic differentiation. RNAs were extracted after differentiation day 5. Data are expressed
relative to control-infected cells (empty lentivirus: c) as mean +/2 s.e.m. Differences for each gene are significant (p,0.005) except where indicated.
Experiments were performed in triplicate with n = 4. C. ERRa represses Runx2 transcriptional activities. C3H10T1/2 cells were transfected with OSE6-
Luc (Runx2-responsive) or ERRE-Luc (ERRa-responsive) plasmid together with the indicated amount of Runx2, and fixed amounts of ERRa or ERRc, as
indicated. CMV-renillaLuc was added as a transfection efficiency control and PGC-1a-encoding plasmid was added together with ERR for the right
panel as indicated. Results are expressed as fold activation over transfection with activator and expressed as the average of a typical triplicate
experiment (out of three) with error bars representing S.D. *: p,0.05; **: p,0.01; ***: p,0.005; ns: non significant.
doi:10.1371/journal.pone.0054837.g003
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osteoclast differentiation and/or activities in response to bone loss
induced by rosiglitazone, a thiazolidinedione prescribed for the
treatment of insulin resistance and diabetes [33].
The actual role of ERRa in osteoblast differentiation in vitro
(inducer or inhibitor of differentiation?) is controversial and has
been thoroughly discussed in our recently published review [27].
However, the absence of ERRa has been associated to an
increased capacity of mesenchymal cells (MCs) to differentiate in
osteoblasts ex vivo [23,24]. Conversely MCs were less prone to
differentiate into adipocytes in the absence of the receptor [22]
leading to reduced fat marrow in ERRaKO animals [23]
suggesting that ERRa is an early switch factor influencing MCs
differentiation towards the adipocyte pathway at the expense of
the osteoblastic one. ERRa has been suspected of additional
effects in later steps of osteoblast maturation which may be
mediated by osteopontin (opn), a downstream positive target of the
receptor [30]. Indeed opn has been shown to reduce bone
mineralization and its absence in KO mice confers resistance to
ovx-induced bone loss [34], as does inactivation of ERRa.
The conditional KO approach described in the present report
allows us to discriminate between the early (MCs commitment)
and late (osteoblast maturation) effects of ERRa. To inactivate
a floxed ERRa allele, we indeed expressed the Cre recombinase
Figure 4. Conditional inactivation of ERRa in vivo does not
impact bone ageing. Bone volume fraction (BV/TV; A), bone mineral
density (BMD; B), trabecular number (Tb N; C), trabecular spacing (Tb
Sp; D) and trabecular thickness (Tb Th; E) were determined by microCT-
scan at 14 (white bars) and 24 wk (black bars) in the femur of female
control (c) and conditional ERRa knock-out (cKO) mice (n = 6 to 11 per
group). Error bars represent s.e.m. *: p,0.05; ***: p,0.005; ns: non
significant.
doi:10.1371/journal.pone.0054837.g004
Figure 5. Conditional inactivation of ERRa in vivo protects
against ovariectomy-induced bone loss. A. Photograph of uteri in
sham-operated or ovariectomized (ovx) control (c) or cKO mice. B–F.
Same parameters as in Fig. 3 were determined in females either sham-
operated (white bars) or two weeks after ovariectomy (ovx; black bars).
BV/TV (G) and BMD (H) were determined in male mice either sham-
operated (white bars) or four weeks after orchidectomy (orx; black bars).
All mice (n = 6 to 10 per group) were 14 wk old at the end of the
experiment. Error bars represent s.e.m. *: p,0.05; ***: p,0.005; ns: non
significant.
doi:10.1371/journal.pone.0054837.g005
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under the control of a Col1a promoter fragment, driving
expression during mid stages of osteoblast differentiation, i.e. well
after MCs commitment to the osteoblastic lineage [28]. As
a consequence we observed a decrease in ERRa expression only
during mid to late stages of osteoblast maturation ex vivo, whereas
the receptor is normally present in pre-osteoblasts. Consistently the
expression of Runx2, an early differentiation marker and inducer
[8], was normally regulated during cKO pre-osteoblast differen-
tiation in contrast to what observed in complete ERRaKO mice,
where a marked increase of Runx2 expression had been observed
[23,24]. However, the expression of mid- to late markers of
osteoblast differentiation was deregulated in cKO-originating cells,
in a manner similar to that observed in complete ERRaKO
animals. In this respect our data suggest that ERRa may reduce
osteoblast differentiation by antagonizing Runx2 transactivation
capacities, in a manner similar to that demonstrated for the closely
related ERRc receptor [26].
Age-induced bone loss in cKO mice was similar to the one
measured in control animals. This excludes that the activities of
ERRa during osteoblast maturation may mediate age-dependent
bone loss. It is tempting to rather speculate that the activities of
ERRa as a repressor of MCs commitment to the osteoblastic
lineage are involved in this phenomenon. However, we cannot
formally exclude the impact of a yet uncharacterized primary
activity of ERRa outside the bone compartment that would
result in age-related bone loss. Investigating the bone response
of ERRa cKO animals to gonadectomy revealed that males
were normally sensitive whereas females were completely
protected from bone loss. This situation is actually identical to
the one observed in complete ERRaKO mice and confirms
a gender-dependent effect of the receptor in bone. More
importantly our results demonstrate that ERRa contributes to
ovariectomy-induced bone loss via its activities on osteoblast
maturation, and not through the regulation of MCs commit-
ment. These results are summarized on Figure 6.
Together with data published by other laboratories, our results
suggest that ERRa could be a promising target for the design of
innovative therapies against bone loss, specifically in females. In
this respect, we previously demonstrated that expression of the
receptor in bone is not modified according to the estrogen status in
mice [35]. Although ERRa is an orphan receptor, several
synthetic compounds have been identified that modulate its
activities and impact on its stability [10–14]. A pharmacological
approach could thus be considered to specifically impact on the
receptor. However complete inhibition of the receptor can be
expected to lead to various undesired side effects on metabolism.
For instance, given the role of ERRa as a switch factor in MCs
commitment, its inhibition, while promoting osteoblast differen-
tiation, would likely affect adipogenesis and thereby lipid storage
and consumption. A more reliable approach would consist in
impacting only the late osteoblast activities of the receptor,
although this would solely be efficient against estrogen deficiency-
induced bone loss. Such a compound, modulating a specific subset
of the receptor’s activities, is still to be identified.
Materials and Methods
Animals
Col1a-Cre mice have been described elsewhere [28]. ERRafl/fl
(Esrra,tm1ICS. mouse line) animals have been generated in the
Institut Clinique de la Souris (Illkirch-Graffenstaden). For
genotyping, DNA extracted from organs using conventional
methods was PCR amplified using Eurobio kit. PCR cycle used:
94uC, 30 sec; 62uC, 30 sec; 72uC, 1 min. PCR products were
analysed on 1.2% agarose gels.
Primers Used for Genotyping
a: 59-GCCCCCCTTGGCCCCCCTTAGCCCCCTCCC-39
b: 59-CCCTGCTTCTGTGCCCTTTGC-39
c: 59-CCACCACTGCCCAGCTTCAC-39
For surgery, animals were anesthetized with sodium pentobar-
bital. Testes were ligatured and cut through an incision in the
scrotum. Ovaries were removed through an incision in the flanks.
Animals were sacrificed 2 wk after operation.
Figure 6. In vivo and ex vivo effects of ERRa on bone. ERRa impairs the later steps of osteoblastic differentiation. The results presented here
show that these activities are involved in bone loss induced by estrogen deficiency and may involve the repression of Runx2- driven transcriptional
activities. In contrast, these activities are not involved in bone sensitivity to ageing. Data published by other show that ERRa also promotes the early
commitment of mesenchymal stem cells (MSCs) toward the adipocytic pathway while restricting the osteoblastic one. We hypothesize that these
early activities are responsible, at least in part, for bone loss induced by ageing. See text for details and references.
doi:10.1371/journal.pone.0054837.g006
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All animal experiments were performed in the Plateau deBiologie
Expe´rimentale de la Souris (PBES; ENS Lyon) under animal care
procedures, conducted in accordance with the guidelines set by the
European Community Council Directives (86/609/EEC) and
approved by the ENS Lyon ethical committee. Animals were in
C57black6 background and had access to food and water ad libitum.
Mice were sacrificed by cervical dislocation at 10 a.m.
X-ray Microcomputed Tomography Analysis
3D microarchitecture of the femur was evaluated using a high-
resolution (8 mm) microtomographic imaging system (eXplore
Locus, GE, USA). A 3D region within the secondary spongiosa in
the proximal metaphysis of the femur was reconstructed,
beginning 500 mm proximal to the growth plate and extending
to 1.5 mm. Cortical bone was reconstructed from a 1 mm thick
region of interest centered on the diaphysis, 5 mm distal from the
proximal growth plate. Morphometric parameters were computed
using the Advanced Bone Analysis Microview Software (GE).
Calvarial Cell Cultures
Calvariae were isolated from 1–5 day old mice and digested for
1 hr in collagenase (Sigma). After centrifugation, cell pellet was set
in culture in six-well plates in aMEM supplemented with 10%
fetal calf serum (FCS), 1% penicillin/streptomycin. Cells were
induced to differentiate into osteoblasts with 50 mg/ml L-ascorbic
acid and 10 mM b-glycerophosphate. Culture medium was
replaced every 2 to 3 days. For immunofluorescence, cells were
fixed in 4% paraformaldehyde for 10 min, then permeabilized
with 0.5% Triton, 0.3% BSA in PBS for 5 min. Saturation was
performed in 0.3% BSA in PBS for 30 min. Primary antibodies
(anti-ERRa from Santa Cruz diluted 1/50; anti-collagen1 from
Novotech diluted 1/200) were added or 3 hrs at RT. Secondary
antibodies from Jackson (anti-mouse-Alexa488 diluted 1/1000) or
Interchim (anti-rabbit-Alexa647 diluted 1/1000) were incubated
for 1 hr at RT. Hoescht staining was diluted 1/20,000 and
incubated for 10 min. For ALP staining, cells were rinsed with
PBS, then fixed with 4% (v/v) formaldehyde for 5 min. After 3
washes with H2O, cells were stained using the alkaline phospha-
tase fast red violet kit (Sigma) following the indications provided by
the manufacturer. Detection of mineralization activity was
performed 15 days after the onset of differentiation. To this end
cells were washed with PBS, then stained with 5% silver nitrate
under UV irradiation for 10 min, then washed and dried.
For lentivirus construction, flagged human-ERRa fragment was
inserted into the blunted BamHI site of the pRRL.PPT.SF.i2GFPp
plasmid. This plasmid was provided by the Lentivus Production
platform (ENS Lyon), which produced the recombinant lentivirus.
Virus titers were determined upon infection of 293T cells. Calvarial
cells were infected (MOI 5 in PBS) one day after induction of
differentiation. Empty virus was used as a control.
Expression Analysis
RNAs were purified using Guanidinium thiocyanate/phenol/
chloroforme extraction. Total RNAs were reverse transcribed
using iScript retrotranscription kit (Biorad). Quantitative PCR
were performed using the iQ SYBR-Green kit (Biorad) in
duplicate on a Biorad Cfx1000 apparatus using standard
procedures. Results were analysed using the DDCt method
normalized to the expression of the 36b4 housekeeping gene.
Sequence of the Primers Used for Real time PCR
36b4:59-ACCTCCTTCTTCCAGGCTTT-39 and 59-
CCCACCTTGTCTCCAGTCTTT-39; ALP: 59-GCCCTCCA-
GATCCTGACCAA-39 and 59- GCA-
GAGCCTGCTGGTCCTTA-39;
Col1a: 59-CTGACGCATGGCCAAGAAGA-39 and 59-GCA-
TACCTCGGGTTTCCACG-39; ERRa: 59-
CAAACGCCTCTGCCTGGTCT-39 and 59-ACTC-
GATGCTCCCCTGGATG-39; Ocn: 59-ACCTCACAGATGC-
CAAGCCC-39 and 59-AGCGCCGGAGTCTGTTCACT-39;
Opn: 59-TCTCCTTGCGCCACAGAATG-39 and 59-
TCGTCCATGTGGTCATGGCT-39; Runx-2:59-
GACGTGCCCAGGCGTATTTC-39 and 59-
GGAACTGCCTGGGGTCTGAA-39.
For Western blot analysis, cells were lysed in RIPA buffer. 30 mg
proteins were resolved on a 10% SDS-PAGE, blotted onto
nitrocellulose membrane (GE-Healthcare) and probed with anti-
bodies (ERRa from Genetex, hsp90 from Santa Cruz) after
saturation.
Analysis of Transcriptional Activities
C3H10T1/2 cells were cultured in MEM supplemented with
10% FCS. For transient transfection, 15.103 cells were seeded in
96-well plates and transfection using 0.75 ml of ExGen500
(Euromedex), 12.5 ng firefly luciferase reporter plasmid (ERRE-
Luc or OSE6-Luc) and the indicated amount of activator-
encoding plasmids. 12.5 ng CMV-renilla Luciferase were added
to normalize transfection efficiency and pSG5 plasmid was added
as a carrier up to 125 ng. Cells were lyzed 48 h after transfection
and reporter activities were determined using standard methods.
All transfections were performed in triplicate. pSG-ERRa, pSG-
ERRc and ERRE-luc have been described in [36], CMV-Runx2
and 6OSE-Luc (generous gifts of Patricia Ducy) in [31].
Statistical Analysis
Statistical significance was analyzed using one-way ANOVA.
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